Martin Babler serves as President, Chief Executive Officer, and Director at Alumis Inc., a clinical-stage biopharmaceutical company leveraging advanced AI and precision medicine to develop transformative therapies for immune-mediated diseases. With more than 25 years of experience in the biopharmaceutical industry, Babler brings a proven track record of driving commercial success, strategic growth, and innovative pipeline advancement across oncology, immunology, and rare diseases. Prior to joining Alumis in 2023, Babler was CEO of Syros Pharmaceuticals, where he led the company's strategic repositioning and pipeline prioritization in oncology and other high-need areas. Previously, as CEO of bluebird bio, he spearheaded the FDA approval and commercial launch of ZYNTEGLO, the first gene therapy for transfusion-dependent beta-thalassemia, and advanced multiple programs in severe genetic diseases, navigating complex regulatory and market challenges to deliver pioneering treatments to patients. Babler's earlier career at Genentech, a Roche company, included senior leadership roles such as Head of U.S. Oncology Commercial and Head of U.S. Commercial Operations for Immunology, Rare Diseases, and Infectious Diseases, where he contributed to the blockbuster launches of therapies like TECENTRIQ and XOLAIR. At Alumis, he is steering the company's ESKIM platform—a next-generation suite of AI-enabled tools—to accelerate the discovery and development of targeted immunomodulators, positioning the firm at the forefront of precision immunology.